RecruitingNot ApplicableNCT06455904

Effects Of Concentric Cycling Training Protocol During (Neo)Adjuvant Chemotherapy in Breast Cancer Patients: PROTECT-07 Study

Sponsor

Centre Paul Strauss

Enrollment

156 participants

Start Date

May 30, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

The association of anthracyclines (ANT) and paclitaxel (Tax) is one of the main treatments used in breast cancer. These treatments are known to induce severe side effects such as a decrease in overall exercise capacity (physical condition) in response to muscle and cardiorespiratory alterations. If exercise may be an effective preventive strategy, it seems important to prescribe the most efficient exercise modality. Among them, concentric cycling (i.e., classic cycling) can significantly induce metabolic stimulus, which is needed for maintaining exercise capacity. The PROTECT-07 study aims to demonstrate the superiority of a training program based on concentric cycling during chemotherapy compared to standard treatment. The duration of the training program is 15 weeks with one session per week.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (called PROTECT-07) is testing whether a structured cycling exercise program can help protect the heart in women with breast cancer who are undergoing chemotherapy. Certain chemotherapy drugs can damage the heart, and exercise may help prevent this. **You may be eligible if...** - You are a woman aged 18 or older - You have stage I to III breast cancer - You are about to start a chemotherapy regimen that includes anthracycline, cyclophosphamide, and weekly paclitaxel (with or without trastuzumab) - You are affiliated with a French social security system - You can speak, read, and understand French **You may NOT be eligible if...** - You have already received chemotherapy - You have a known heart or blood vessel condition - You have a psychiatric, musculoskeletal, or neurological condition that prevents safe exercise testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETraining sessions

The training program will be performed during 15 weeks, with one session per week.

Locations(2)

Hôpitaux civils de Colmar

Colmar, France

Institut de cancérologie Strasbourg Europe

Strasbourg, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06455904

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828764 locations

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521158 locations

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT0560144010 locations

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT045238571 location